Snapshot from Jun 11, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Medpace Securities Fraud Class Action
Business class action lawsuit

Medpace Securities Fraud Class Action

Analysis based on 21 articles · First reported May 21, 2026 · Last updated Jun 08, 2026

Sentiment
-50
Attention
4
Articles
21
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuits against Medpace by Rosen Law Firm and Robbins Geller Rudman & Dowd LLP are likely to negatively impact Medpace's stock price and reputation. Investors who purchased Medpace common stock during the Class Period may seek compensation, potentially leading to financial liabilities for Medpace.

pharmaceuticals biotechnology legal services
Event Summary

Multiple law firms, including Rosen Law Firm and Robbins Geller Rudman & Dowd LLP, have announced class action lawsuits against Medpace Holdings, Inc. The lawsuits allege that Medpace made false and misleading statements to investors between April 22, 2025, and February 9, 2026, regarding its projected book-to-bill ratio and backlog cancellation rates. Specifically, Medpace is accused of continuously touting 'well behaved' cancellation rates and providing overly positive growth expectations that could not maintain a projected 1.15 book-to-bill ratio. On February 9, 2026, Medpace released fourth-quarter 2025 earnings results, revealing a book-to-bill ratio of 1.04, which was significantly below its guidance, causing its stock price to fall by nearly 16%. Investors who suffered losses are encouraged to join the class action lawsuits, with a lead plaintiff deadline of June 8, 2026.

Key Actions
98 Rosen Law Firm announces class action lawsuit Medpace
95 Robbins Geller Rudman & Dowd LLP announced class action Medpace
90 Medpace made false statements
Entities Involved
stock
Medpace
Medpace is the defendant in a class action lawsuit alleging that it made false and misleading statements regarding its book-to-bill ratio and cancellation rates, leading to a significant drop in its stock price.
Importance 100 Sentiment -60
priv
Rosen Law Firm
Rosen Law Firm is actively encouraging investors to join the class action lawsuit against Medpace and is seeking lead plaintiffs for the case.
Importance 80 Sentiment 35
priv
Robbins Geller Rudman & Dowd LLP
Robbins Geller Rudman & Dowd LLP is another law firm that has announced a class action lawsuit against Medpace and is seeking lead plaintiffs.
Importance 70 Sentiment 35
per
Philip Kim
Philip Kim, an attorney at Rosen Law Firm, is a contact person for investors interested in joining the Medpace class action lawsuit.
Importance 60 Sentiment 30
per
Lawrence Rosen
Lawrence Rosen, founding partner of Rosen Law Firm, is involved in the firm's efforts to represent investors in securities class actions, including the one against Medpace.
Importance 60 Sentiment 30
per
Ken Dolitsky
Ken Dolitsky, an attorney at Robbins Geller Rudman & Dowd LLP, is a contact for investors regarding the Medpace class action lawsuit.
Importance 50 Sentiment 30
per
Michael Albert
Michael Albert, an attorney at Robbins Geller Rudman & Dowd LLP, is a contact for investors regarding the Medpace class action lawsuit.
Importance 50 Sentiment 30
govactor
United States — United States District Court for the Northern District of California
The United States — United States District Court for the Northern District of California is the venue where the class action lawsuit against Medpace is captioned.
Importance 20 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.